Category

News
Companies join forces to target different T cell subsets and combat cancer CAMBRIDGE, Mass., PARIS and SHANGHAI – Oct. 15, 2018 – HiFiBiO Therapeutics, a world leader in the discovery of therapeutic antibodies through single-cell screening and analysis, announced today the acquisition of H-Immune Therapeutics, an early-stage biotechnology company engaged in the discovery and development...
Read More
Santa Monica, Calif. and Hong Kong, October 2, 2018 – Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics, a biotechnology company focused on the discovery of therapeutic antibodies through single B cell screening and analysis, announced the companies have entered into a research collaboration and license agreement to develop technology supporting the discovery of...
Read More
Global pharmaceutical leader selects innovative single-B-cell technology to generate breakthrough therapies CAMBRIDGE, Mass., SHANGHAI, China, and PARIS, France – July 30, 2018 – HiFiBiO Therapeutics, a world leader in the discovery of therapeutic antibodies through single-B-cell screening and analysis, today announced a multi-target agreement with Takeda Pharmaceutical Company Limited (Takeda) to enable the discovery of...
Read More
Multinational biotherapeutics company announces a new leadership team, expands its global footprint and advances an innovative portfolio of immune modulators for unmet medical needs CAMBRIDGE, Mass., HANGZHOU, China, and PARIS – May 16, 2018 – HiFiBiO Therapeutics, a world leader in the discovery of therapeutic antibodies through single-B-cell screening and analysis, today announced the completion...
Read More
CAMBRIDGE, MA, AND PARIS, FRANCE, 12 October, 2017 – HiFiBiO and collaborators describe the application of droplet microfluidics to characterize immune responses at the single-cell level in work published in Nature Biotechnology. Eyer et al‘s paper, “Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring” describes DropMap, “a powerful and elegant technology for the phenotypic analysis of antibody-secreting cells...
Read More
Guiding principles of value creation through collaborative innovation in pharmaceutical research HiFiBiO CEO Liang Schweizer and COO Jeff He outline the importance of breaking down common barriers in collaborations, propose four guiding principles for such co-operation and offer a framework to reach value inflection points quicker. Abstract Open innovation has become the main trend in...
Read More
HiFiBiO receives recognition as one of Biocentury Innovations’ Emerging Companies in an article entitled “Mining for Functionality” published May 16th in Biocentury’s online magazine. Paris, France, May 29th, 2016 — HiFiBiO receives recognition as one of Biocentury Innovations’ Emerging Companies in an article entitled “Mining for Functionality” published May 16th. To see the Biocentury article...
Read More
Paris, France. In the inauguration of the new microfluidics center the Institut Pierre Gilles de Gennes (IPGG), French President François Hollande recognized HiFiBiO SAS, a start-up company from Ecole Superieure de Physique and Chimie Industrielles de la ville de Paris (ESPCI), for its innovative application of single cell microdroplet technology for antibody discovery and development....
Read More
CAMBRIDGE, MA AND PARIS, FRANCE, August 13, 2015, 2015 – HiFiBiO SAS announced today the company has achieved a milestone in its research collaboration with Pfizer Inc., triggering a milestone payment to HiFiBiO. The focus of the collaboration, originally signed in 2014, is the development and validation of HiFiBiO’s proprietary, high throughput antibody discovery platform for deep...
Read More
Exploring New Antibody Discovery Platforms – While current antibody discovery technologies, such as hybridomas, are highly reliable, they are also inefficient in terms of percentage of antigen-specific B cells identified during screening. HiFiBiO and Janssen Biotech, Inc. are collaborating to evaluate the company’s single cell technology for genetically characterizing individual cells as a potential new...
Read More